First-in-Human Study of PLX-61639
Phase 1
155
about 4.8 years
18+
10 sites in AZ, CA, MA +6
What this study is about
This trial is testing a new medication called PLX-61639 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if the medication is safe and how it works in the body.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take PLX-61639
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Dose-Limiting Toxicities, Treatment Emergent Adverse Events
Secondary: Dose reductions due to Adverse Events, Duration of response (DoR) to PLX-61639, Pharmacokinetics of PLX-61639: AUC0-last, Pharmacokinetics of PLX-61639: Cmax, Pharmacokinetics of PLX-61639: Tmax, Progression Free Survival (PFS) of PLX-61639, Radiographic response to PLX-61639
Oncology